Gilead to Acquire Biotech Firm Arcellx for $7.8B
What happened
Pharmaceutical company Gilead is acquiring U.S. biotech firm Arcellx in a deal valued at up to $7.8 billion. The acquisition is a sign of ongoing consolidation within the advanced therapeutics sector.
Why it matters
- The deal structure includes $115 per share in cash, which represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026. Shareholders could also receive an additional $5 per share through a contingent value right if the lead drug's cumulative global net sales reach $6 billion by the end of 2029. - This acquisition gives Gilead full control of Arcellx's lead candidate, anito-cel, a CAR T-cell therapy for treating relapsed or refractory multiple myeloma, a type of blood cancer. The U.S. Food and Drug Administration (FDA) has accepted the therapy's Biologics License Application, with a decision expected by December 23, 2026. - The two companies were not strangers; Gilead's cell therapy subsidiary, Kite, had been in a collaboration with Arcellx since 2022 to co-develop and co-commercialize anito-cel. This acquisition eliminates future profit-sharing, milestone payments, and royalties that Gilead would have owed Arcellx. - The purchase is a strategic move to bolster Gilead's cell therapy division, which reported a 7% sales decline in 2025 and was projected to slide another 10% in 2026. Gilead originally entered the cell therapy space with its $12 billion acquisition of Kite Pharma in 2017. - Beyond the lead drug, the deal includes Arcellx's D-Domain CAR technology platform. This platform is designed to create target-binding domains with improved specificity, which could be used to develop next-generation cell therapies and may be pivotal to Gilead's in-vivo cell therapy research. - Arcellx's broader clinical-stage pipeline includes treatments for other cancers such as relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). - The acquisition takes place within a rapidly growing market for CAR T-cell therapies, which was valued at over $6 billion in 2024 and is projected by some analysts to exceed $30 billion by 2030.
Key numbers
- biotech firm Arcellx in a deal valued at up to $7.8 billion.
- - The deal structure includes $115 per share in cash, which represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026.
- Shareholders could also receive an additional $5 per share through a contingent value right if the lead drug's cumulative global net sales reach $6 billion by the end of 2029.
- Food and Drug Administration (FDA) has accepted the therapy's Biologics License Application, with a decision expected by December 23, 2026.
What happens next
- Shareholders could also receive an additional $5 per share through a contingent value right if the lead drug's cumulative global net sales reach $6 billion by the end of 2029.
- Food and Drug Administration (FDA) has accepted the therapy's Biologics License Application, with a decision expected by December 23, 2026.
- This platform is designed to create target-binding domains with improved specificity, which could be used to develop next-generation cell therapies and may be pivotal to Gilead's in-vivo cell therapy research.
Quick answers
What happened in Gilead to Acquire Biotech Firm Arcellx for $7.8B?
Pharmaceutical company Gilead is acquiring U.S. biotech firm Arcellx in a deal valued at up to $7.8 billion. The acquisition is a sign of ongoing consolidation within the advanced therapeutics sector.
Why does Gilead to Acquire Biotech Firm Arcellx for $7.8B matter?
The deal structure includes $115 per share in cash, which represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026. Shareholders could also receive an additional $5 per share through a contingent value right if the lead drug's cumulative global net sales reach $6 billion by the end of 2029. This acquisition gives Gilead full control of Arcellx's lead candidate, anito-cel, a CAR T-cell therapy for treating relapsed or refractory multiple myeloma, a type of blood cancer. The U.S. Food and Drug Administration (FDA) has accepted the therapy's Biologics License Application, with a decision expected by December 23, 2026. The two companies were not strangers; Gilead's cell therapy subsidiary, Kite, had been in a collaboration with Arcellx since 2022 to co-develop and co-commercialize anito-cel. This acquisition eliminates future profit-sharing, milestone payments, and royalties that Gilead would have owed Arcellx. The purchase is a strategic move to bolster Gilead's cell therapy division, which reported a 7% sales decline in 2025 and was projected to slide another 10% in 2026. Gilead originally entered the cell therapy space with its $12 billion acquisition of Kite Pharma in 2017. Beyond the lead drug, the deal includes Arcellx's D-Domain CAR technology platform. This platform is designed to create target-binding domains with improved specificity, which could be used to develop next-generation cell therapies and may be pivotal to Gilead's in-vivo cell therapy research. Arcellx's broader clinical-stage pipeline includes treatments for other cancers such as relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The acquisition takes place within a rapidly growing market for CAR T-cell therapies, which was valued at over $6 billion in 2024 and is projected by some analysts to exceed $30 billion by 2030.
